Should not be used in asthma & for treatment of acute episodes of bronchospasm (ie, as rescue therapy). Immediate hypersensitivity reactions after administration. Paradoxical bronchospasm. Clinically significant CV effect in some patients as measured by increases in pulse rate, BP, &/or symptoms. Significant hypokalaemia in some patients, potentially leading to adverse CV effects. Increases in plasma glucose. Patients w/ CV disorders, especially ischaemic heart disease, severe cardiac decompensation, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, HTN, & aneurysm; convulsive disorders or thyrotoxicosis; known or suspected prolongation of the QT interval (eg, QT >0.44 sec); patients who are unusually responsive to sympathomimetic amines; patients w/ a history of MI during the previous yr, unstable or life-threatening cardiac arrhythmia, hospitalized for heart failure during the previous yr or w/ a diagnosis of paroxysmal tachycardia (>100 beats per min). Patients w/ a planned operation w/ halogenated hydrocarbon anaesth. Should not be used in conjunction w/ any other medication containing long-acting β
2-adrenergic agonists. Patients who have been taking inhaled, short-acting β
2-adrenergic agonists on a regular basis (eg, 4 times a day) should be instructed to use them only for symptomatic relief of acute resp symptoms.
Sign Out
